title: [Serial changes in serum levels of laminin and type III procollagen N-terminal peptide after transarterial embolization (TAE) in hepatocellular carcinoma].
abstract: In the present study, we have measured the serum levels of laminin and PIIIP in patients with various liver disease, and studied serial changes in serum laminin and PIIIP after TAE. The following results were obtained. 1) Serum levels of laminin as well as PIIIP were significantly higher in liver cirrhosis, liver cirrhosis with hepatocellular carcinoma and chronic active hepatitis compared to that in healthy controls, and serum levels of laminin revealed significant correlation with serum levels of PIIIP in liver cirrhosis with hepatocellular carcinoma. While serum levels of PIIIP were elevated significantly in acute hepatitis, serum levels of laminin were not elevated. 2) There was no significant difference in the serum levels of laminin between liver cirrhosis and liver cirrhosis with hepatocellular carcinoma. The results suggested that serum levels of laminin as well as PIIIP cannot be a specific marker of hepatocellular carcinoma. 3) In the study of serial changes of these peptides after TAE, changes in the serum levels of laminin in effective cases were different from those in ineffective cases. The results suggested that measurement of serial changes in the serum levels of laminin after TAE was considered to be useful for evaluating the effectiveness of TAE. Also, changes in serum levels of laminin after TAE were different from those observed in serum PIIIP. The results suggest that mechanism of release of laminin into serum in hepatocellular carcinoma may be different from that of PIIIP.
authors.affiliation: Second Department of Internal Medicine, Kanazawa University.
authors.forename: H
authors.initials: H
authors.lastname: Matsuda
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000628:therapy; D004317:Doxorubicin / Q000008:administration & dosage; D004621:Embolization, Therapeutic; D005260:Female; D006499:Hepatic Artery; D006521:Hepatitis, Chronic / Q000097:blood; D006801:Humans; D007459:Iodized Oil / Q000008:administration & dosage; D007797:Laminin / Q000097:blood*; D008103:Liver Cirrhosis / Q000097:blood; D008113:Liver Neoplasms / Q000097:blood* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D010446:Peptide Fragments / Q000097:blood*; D011347:Procollagen / Q000097:blood*
chemical_list: D007797:Laminin; D008937:Mitomycins; D010446:Peptide Fragments; D011347:Procollagen; C041876:procollagen Type III-N-terminal peptide; D016685:Mitomycin; D007459:Iodized Oil; D004317:Doxorubicin